Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.

Experimental hematology - 1 Mar 2008

Munugalavadla Veerendra, Sims Emily C, Chan Rebecca J, Lenz Stephen D, Kapur Reuben

Abstract excerpt

OBJECTIVE: Oncogenic activation loop mutations of KIT are observed in acute myeloid leukemia (AML) and in myeloproliferative disorders (MPD); however, the signaling pathways that contribute to transformation via these mutations in vivo are not known. Previous studies have demonstrated hyperactiva...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Cells
Share to Bone Marrow Transplantation
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-kit

Share to Spleen

Source

Identifiers

PMID: 18179858
DOI: 10.1016/j.exphem.2007.11.008

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18179858-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Requirement for p85alpha regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT.PMID 18179858Read ↗

Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease.Semantic proximity Read ↗

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.Semantic proximity Read ↗

The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm.Semantic proximity Read ↗

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.Semantic proximity Read ↗

Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.Semantic proximity Read ↗

KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.Semantic proximity Read ↗

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.Semantic proximity Read ↗

The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.Semantic proximity Read ↗

Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.Semantic proximity Read ↗

Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.Semantic proximity Read ↗

Somatic activation of oncogenic <i>Kras</i> in hematopoietic cells initiates a rapidly fatal myeloproliferative disorderSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.